Table 3 LncRNAs involved in tumor diagnostic and prognostic prediction of pancreatic cancer
LncRNA | Diagnosis or prognosis | Sample | AUC | AUC when combined with non-lncRNA parameters | References |
|---|---|---|---|---|---|
Linc-pint | Diagnosis (PDAC vs healthy control) | Plasma | 0.87 | 0.92 (Combined with CA19-9) | [77] |
SNHG15 | Diagnosis (PDAC vs control) | Plasma/Tissues | 0.727/0.785 | – | [78] |
LINC01638 | Diagnosis (PDAC vs healthy control) | Plasma | 0.8760 | – | [79] |
LncRNA ABHD11-AS1 | Diagnosis (PDAC vs healthy control) | Plasma | 0.887 | 0.982 (Combined with CA19-9) | [80] |
LncRNA HULC | Diagnosis (PDAC vs healthy control) | Plasma (extracellular vesicle) | 0.94 | – | [81] |
8-lncRNA signature (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) | Diagnosis (resectable PDAC vs healthy control) | Plasma (extracellular vesicle) | 0.949 | – | [82] |
LncRNA HOTAIR and PVT1 | Diagnosis (PDAC vs healthy control) | Salivary | 0.909 | 0.870 (Combined with CA19-9) | [83] |
Diagnosis (PDAC vs benign pancreatic lesions) | Salivary | 0.909 | – | ||
Diagnosis (PDAC vs IPMN) | Plasma (extracellular vesicle) | 0.91 | – | ||
8-lncRNA signature (ADARB2-AS1, ANRIL, GLIS3-AS1, LINC00472, MEG3, PANDA, PVT1 and UCA1) | Diagnosis (Malignant IPMN vs benign IPMN) | Plasma | 0.77 | 0.9244 (A model combining the 8-lncRNA signature, the 5-miRNA signature, radiomic features, standard worrisome features (WF), gender, and presence of jaundice | [85] |
LncRNA UFC1 | Diagnosis (PDAC vs healthy control) | Plasma | 0.810 | – | [92] |
LncRNA AFAP-AS1 | Prognosis | Tissues | 0.8669 (6 months)/0.9370 (1 year) | – | [88] |
5-lncRNA signature (C9orf139, MIR600HG, RP5-965G21.4, RP11-436K8.1, and CTC-327F10.4) | Prognosis | Tissues | 0.742 | – | [89] |
8-lncRNA signature (RP3.470B24.5, CTA.941F9.9, RP11.557H15.3, LINC00960, AP000479.1, LINC00635, LINC00636 and AC073133.1) | Prognosis | Tissues | 0.647 | 0.716 (Combined a panel of 8-mRNA signature) | [90] |
5-lncRNA signature (RP11-159F24.5, RP11-744N12.2, RP11-388M20.1, RP11-356C4.5, CTC-459F4.9) | Prognosis | Tissues | 0.70 | 0.76 (Combined with TNM stage) | [91] |
9-immune related lncRNA signature (AL138966.2, AL133520.1, AC142472.1, AC127024.5, AC116913.1, AC083880.1, AC124016.1, AC008443.5, and AC092171.5) | Prognosis | Tissues | 0.703 | – | [93] |